Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic human umbilical cord tissue-derived mesenchymal stem cells
- Development stage
- Phase 2
- Lead developer
- Novo Cellular Medicine Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Allogeneic human umbilical cord tissue-derived mesenchymal stem cells (UC-MSCs) are an investigational cell therapy developed by Novo Cellular Medicine Institute LLP for the treatment of relapsing-remitting multiple sclerosis (RRMS). These cells are harvested from the Wharton's jelly of umbilical cord tissue and are characterized by their potent immunomodulatory, anti-inflammatory, and potentially neuroprotective properties. In RRMS, UC-MSCs are hypothesized to suppress the aberrant autoimmune response by modulating the activity of T-cells and B-cells and secreting paracrine factors that promote an environment conducive to neural repair and remyelination. This specific therapeutic product was evaluated in a Phase I/II clinical trial (NCT01531062) in combination with "liberation therapy," a percutaneous transluminal angioplasty procedure intended to treat chronic cerebrospinal venous insufficiency (CCSVI).
- Other names
- UC-MSCumbilical cord-derived mesenchymal stem cellsWharton's jelly-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic human umbilical cord tissue-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic human umbilical cord tissue-derived mesenchymal stem cells.